Breast Cancer | Specialty

Managing T-DXd Toxicities in Gastric Cancer

November 3rd 2023

Insights on managing antibody-drug conjugate toxicities for patients with gastric cancer.

Gastric Cancer Treatment: T-DXd

November 3rd 2023

A GI medical oncologist discusses the role of trastuzumab deruxtecan in the gastric cancer treatment space.

Global Perspectives: Evolution of Advanced HER2+ Breast Cancer Treatment

November 2nd 2023

Joseph Gligorov, MD, reviews advances in the treatment of advanced HER2+ breast cancer, shares his global perspective, and explains how ESMO and NCCN guidelines are similar.

Trastuzumab Deruxtecan for Patients With HER2+ Metastatic Breast Cancer (mBC)

November 2nd 2023

Dr Joseph Gligorov highlights the impact of trastuzumab deruxtecan in treating HER2-positive breast cancer due to its impressive results in progression-free survival and overall survival, emphasizing its importance in early treatment, while acknowledging the need to monitor safety issues.

FDA Lifts Clinical Hold on Phase 1 Trial Evaluating XMT-2056 in HER2-Expressing Solid Tumors

October 31st 2023

The FDA has lifted the clinical hold placed on a phase 1 trial evaluating XMT-2056 monotherapy in patients with HER2-high or -low advanced or recurrent solid tumors.

Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy for Patients with Metastatic HR+/HER2– BC: Primary Results from the Randomized Phase III TROPION-Breast01 Trial

October 30th 2023

Expert oncologist Aditya Bardia, MD, reflects on data from the TROPION-Breast01 trial of dato-DXd versus chemotherapy in metastatic HR+/HER2– breast cancer following ESMO 2023.

Dr Tarantino on Understanding the Role of ADC Payloads in Breast Cancer

October 27th 2023

Paolo Tarantino, MD, discusses the importance of understanding the role that payloads play in treatment with antibody-drug conjugates in breast cancer.

MRD and ctDNA Could Shift into Larger Role to Guide Treatment Decisions in Breast Cancer

October 27th 2023

Praveen Vikas, MBBS, discusses what is currently known regarding minimal residual disease testing in breast cancer, expanded on what still needs to be done to bring minimal residual disease and ctDNA testing to clinical practice, and highlighted the evolving treatment paradigm for patients with advanced hormone receptor-positive, HER2-negative breast cancer.

Adverse Events Seen With Second- and Third-Line Therapies in Patients With HER2+ mBC

October 27th 2023

Jane Meisel, MD, discusses managing adverse events in patients receiving second- or third-line treatments for HER2+ metastatic breast cancer, emphasizing close monitoring, patient communication, and symptom-specific interventions.

Clinical Trial Data and Real-World Evidence on Therapy Sequencing for HER2+ mBC

October 27th 2023

Jane Meisel, MD, emphasizes the growing role of real-world evidence in guiding therapy sequencing for HER2+ metastatic breast cancer due to rapidly evolving treatment standards.

Management of ADC Toxicities in Lung Cancer

October 27th 2023

A nurse practitioner provides insights on toxicity management strategies for patients with lung cancer who are receiving antibody-drug conjugates.

Antibody-Drug Conjugates in Lung Cancer

October 27th 2023

A medical oncologist reviews the antibody-drug conjugate landscape in lung cancer.

ImPrint Biomarker Predicts Immunotherapy Response in Patients With HR+/HER2– Breast Cancer

October 25th 2023

Denise M. Wolf, PhD, discusses the methods used to conduct the I-SPY2 study and the implications that immune biomarkers could have on selecting treatment for patients with hormone receptor–positive, HER2-negative breast cancer in the future.

Breaking Ground in Breast, Lung, Gynecologic, and Gastrointestinal Cancers From ESMO 2023: Drs Tarantino, Sands, Vergote, and Janjigian

October 24th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Dr McArthur on Neoadjuvant Pembrolizumab Plus Chemotherapy in ER+/HER2– Breast Cancer

October 23rd 2023

Heather Lynn McArthur, MD, MPH, discusses the primary results from the phase 3 KEYNOTE-756 study of neoadjuvant pembrolizumab plus chemotherapy in early-stage, high-risk, estrogen receptor–positive, HER2-negative breast cancer.

Dr D'Abreo on HER2-Targeted Therapies in HER2+ Breast Cancer

October 23rd 2023

Dato-DXd Provides PFS Benefit in HR+/HER2– Breast Cancer

October 23rd 2023

Datopotamab deruxtecan elicited a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy for patients with hormone receptor-positive, HER2-low or -negative, metastatic breast cancer.

Dr Esteva on the Impact of the MAINTAIN Trial in HR+/HER2– Breast Cancer

October 21st 2023

Francisco J. Esteva, MD, PhD, discusses the impact of the phase 2 MAINTAIN study of treatment with ribociclib following progression on CDK4/6 inhibition in patients with hormone receptor-positive, HER2-negative breast cancer.

Neoadjuvant Pembrolizumab Plus Chemotherapy Boosts pCR in ER+/HER2– Breast Cancer

October 20th 2023

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy generated a statistically significant increase in pathologic complete response vs neoadjuvant placebo plus chemotherapy followed by adjuvant pembrolizumab and endocrine therapy in patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.

Pembrolizumab Plus Neoadjuvant Chemotherapy Produces Long-Term Survival Benefits in High-Risk TNBC

October 20th 2023

Treatment with neoadjuvant pembrolizumab in combination with platinum-containing chemotherapy and followed by adjuvant pembrolizumab improved event-free survival compared with neoadjuvant chemotherapy alone in patients with high-risk triple-negative breast cancer.